{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:31:59Z","timestamp":1792427519114,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T00:00:00Z","timestamp":1415664000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s10549-014-3190-5","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T18:14:39Z","timestamp":1415988879000},"page":"563-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Skin\/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy"],"prefix":"10.1007","volume":"148","author":[{"given":"Joanne","family":"Mortimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kruper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Wai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mendelsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"D\u2019Apuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Tegtmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeet","family":"Dadwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,11]]},"reference":[{"issue":"19","key":"3190_CR1","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.2013.54.0948","volume":"32","author":"SH Giordano","year":"2014","unstructured":"Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2\u2013positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 32(19):2078\u20132099. doi: 10.1200\/jco.2013.54.0948","journal-title":"J Clin Oncol"},{"issue":"26","key":"3190_CR2","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733\u20132743. doi: 10.1056\/NEJMoa064320","journal-title":"N Engl J Med"},{"issue":"21","key":"3190_CR3","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","volume":"30","author":"KL Blackwell","year":"2012","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O\u2019Shaughnessy J (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2\u2013positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 30(21):2585\u20132592. doi: 10.1200\/jco.2011.35.6725","journal-title":"J Clin Oncol"},{"issue":"19","key":"3190_CR4","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Di\u00e9ras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783\u20131791. doi: 10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"issue":"2","key":"3190_CR5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim S-B, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109\u2013119. doi: 10.1056\/NEJMoa1113216","journal-title":"N Engl J Med"},{"issue":"6","key":"3190_CR6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","volume":"14","author":"SM Swain","year":"2013","unstructured":"Swain SM, Kim S-B, Cort\u00e9s J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461\u2013471. doi: 10.1016\/S1470-2045(13)70130-X","journal-title":"Lancet Oncol"},{"issue":"9","key":"3190_CR7","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai Y-F, Ratnayake J, McNally V, Ross G, Cort\u00e9s J (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24(9):2278\u20132284. doi: 10.1093\/annonc\/mdt182","journal-title":"Ann Oncol"},{"issue":"1","key":"3190_CR8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im S-A, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25\u201332. doi: 10.1016\/S1470-2045(11)70336-9","journal-title":"Lancet Oncol"},{"issue":"4","key":"3190_CR9","doi-asserted-by":"crossref","first-page":"542","DOI":"10.6004\/jnccn.2014.0058","volume":"12","author":"WJ Gradishar","year":"2014","unstructured":"Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung B-ME, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R (2014) Breast Cancer Version 3.2014. J Natl Compr Cancer Netw 12(4):542\u2013590","journal-title":"J Natl Compr Cancer Netw"},{"key":"3190_CR10","unstructured":"FDA (2013) FDA Briefing Document Oncologic Drugs Advisory Committee Meeting September 12, 2013, sBLA 125409\/51 Pertuzumab (PERJETA\u00ae); Applicant: Genentech, Inc. FDA publication: Briefing documents"},{"issue":"10","key":"3190_CR11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/cup.12202","volume":"40","author":"LA Brodell","year":"2013","unstructured":"Brodell LA, Hepper D, Lind A, Gru AA, Anadkat MJ (2013) Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors. J Cutan Pathol 40(10):865\u2013870. doi: 10.1111\/cup.12202","journal-title":"J Cutan Pathol"},{"issue":"11","key":"3190_CR12","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.ejca.2010.04.028","volume":"46","author":"E Guttman-Yassky","year":"2010","unstructured":"Guttman-Yassky E, Mita A, De Jonge M, Matthews L, McCarthy S, Iwata KK, Verweij J, Rowinsky EK, Krueger JG (2010) Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 46(11):2010\u20132019. doi: 10.1016\/j.ejca.2010.04.028","journal-title":"Eur J Cancer"},{"issue":"10","key":"3190_CR13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6(10):803\u2013812","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"3190_CR14","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMp1311439","volume":"369","author":"RE Sherman","year":"2013","unstructured":"Sherman RE, Li J, Shapley S, Robb M, Woodcock J (2013) Expediting drug development: the FDA\u2019s new \u201cbreakthrough therapy\u201d designation. N Engl J Med 369(20):1877\u20131880. doi: 10.1056\/NEJMp1311439","journal-title":"N Engl J Med"},{"issue":"24","key":"3190_CR15","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMsa1200223","volume":"366","author":"NS Downing","year":"2012","unstructured":"Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS (2012) Regulatory review of novel therapeutics: comparison of three regulatory agencies. N Engl J Med 366(24):2284\u20132293. doi: 10.1056\/NEJMsa1200223","journal-title":"N Engl J Med"},{"issue":"12","key":"3190_CR16","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S1470-2045(08)70305-X","volume":"9","author":"BJ Edwards","year":"2008","unstructured":"Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL (2008) Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9(12):1166\u20131172","journal-title":"Lancet Oncol"},{"issue":"9816","key":"3190_CR17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, G\u00f3mez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang T-W, Horv\u00e1th Z, Coccia-Portugal M, Domont J, Tseng L-M, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379(9816):633\u2013640","journal-title":"Lancet"},{"issue":"6","key":"3190_CR18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1634\/theoncologist.2012-0129","volume":"18","author":"FJ Esteva","year":"2013","unstructured":"Esteva FJ, Franco SX, Hagan MK, Brewster AM, Somer RA, Williams W, Florance AM, Turner S, Stein S, Perez A (2013) An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist 18(6):661\u2013666. doi: 10.1634\/theoncologist.2012-0129","journal-title":"Oncologist"},{"key":"3190_CR19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/GCO.0b013e328334e44e","volume":"1","author":"J Mortimer","year":"2010","unstructured":"Mortimer J (2010) Managing the toxicities of the aromatase inhibitors. Curr Opin Obstet Gynecol 1:56\u201360","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"1","key":"3190_CR20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clindermatol.2013.05.023","volume":"32","author":"C Dessinioti","year":"2014","unstructured":"Dessinioti C, Antoniou C, Katsambas A (2014) Acneiform eruptions. Clinics in Dermatology 32(1):24\u201334. doi: 10.1016\/j.clindermatol.2013.05.023","journal-title":"Clinics in Dermatology"},{"issue":"1","key":"3190_CR21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdermsci.2010.03.017","volume":"59","author":"S Forsberg","year":"2010","unstructured":"Forsberg S, Rollman O (2010) Re-epithelialization from human skin explant cultures is promoted by ligand-activated HER3 receptor. J Dermatol Sci 59(1):7\u201315. doi: 10.1016\/j.jdermsci.2010.03.017","journal-title":"J Dermatol Sci"},{"issue":"5","key":"3190_CR22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341\u2013354","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3190_CR23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdermsci.2013.05.009","volume":"72","author":"D Nanba","year":"2013","unstructured":"Nanba D, Toki F, Barrandon Y, Higashiyama S (2013) Recent advances in the epidermal growth factor receptor\/ligand system biology on skin homeostasis and keratinocyte stem cell regulation. J Dermatol Sci 72(2):81\u201386. doi: 10.1016\/j.jdermsci.2013.05.009","journal-title":"J Dermatol Sci"},{"issue":"1","key":"3190_CR24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","volume":"102","author":"RE Eilers","year":"2010","unstructured":"Eilers RE, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME (2010) Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 102(1):47\u201353. doi: 10.1093\/jnci\/djp439","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"3190_CR25","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","volume":"23","author":"R Perez-Soler","year":"2005","unstructured":"Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1\/EGFR-targeted agents: Is there a silver lining? J Clin Oncol 23(22):5235\u20135246. doi: 10.1200\/jco.2005.00.6916","journal-title":"J Clin Oncol"},{"key":"3190_CR26","doi-asserted-by":"crossref","unstructured":"Anthony RM, Kobayashi T, Wermeling F, Ravetch JV (2011) Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway. Nature 475 (7354):110\u2013113. doi: http:\/\/www.nature.com\/nature\/journal\/v475\/n7354\/abs\/nature10134-f1.2.html#supplementary-information","DOI":"10.1038\/nature10134"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-3190-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-014-3190-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-3190-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T01:06:22Z","timestamp":1717549582000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-014-3190-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,11]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3190"],"URL":"https:\/\/doi.org\/10.1007\/s10549-014-3190-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,11]]}}}